Purple Biotech Ltd.

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, VRTX has a market cap of 126.2B. Regarding current trading prices, PPBT is priced at $4.49, while VRTX trades at $485.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas VRTX's P/E ratio is 32.43. In terms of profitability, PPBT's ROE is -0.10%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, PPBT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check VRTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, REGN has a market cap of 81.2B. Regarding current trading prices, PPBT is priced at $4.49, while REGN trades at $783.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas REGN's P/E ratio is 18.85. In terms of profitability, PPBT's ROE is -0.10%, compared to REGN's ROE of +0.15%. Regarding short-term risk, PPBT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check REGN's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PPBT is priced at $4.49, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PPBT's ROE is -0.10%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, PPBT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check VRNA's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ARGX has a market cap of 47.5B. Regarding current trading prices, PPBT is priced at $4.49, while ARGX trades at $760.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ARGX's P/E ratio is 32.83. In terms of profitability, PPBT's ROE is -0.10%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, PPBT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ARGX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ALNY has a market cap of 44.1B. Regarding current trading prices, PPBT is priced at $4.49, while ALNY trades at $326.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ALNY's P/E ratio is 142.82. In terms of profitability, PPBT's ROE is -0.10%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, PPBT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ALNY's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PPBT is priced at $4.49, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PPBT's ROE is -0.10%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PPBT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check SGEN's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, INSM has a market cap of 31.8B. Regarding current trading prices, PPBT is priced at $4.49, while INSM trades at $146.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas INSM's P/E ratio is -24.09. In terms of profitability, PPBT's ROE is -0.10%, compared to INSM's ROE of -1.68%. Regarding short-term risk, PPBT is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check INSM's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, BNTX has a market cap of 26.6B. Regarding current trading prices, PPBT is priced at $4.49, while BNTX trades at $109.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas BNTX's P/E ratio is -39.60. In terms of profitability, PPBT's ROE is -0.10%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, PPBT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check BNTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, UTHR has a market cap of 22.8B. Regarding current trading prices, PPBT is priced at $4.49, while UTHR trades at $508.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas UTHR's P/E ratio is 19.11. In terms of profitability, PPBT's ROE is -0.10%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, PPBT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check UTHR's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, MRNA has a market cap of 20.9B. Regarding current trading prices, PPBT is priced at $4.49, while MRNA trades at $53.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas MRNA's P/E ratio is -7.26. In terms of profitability, PPBT's ROE is -0.10%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, PPBT is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check MRNA's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ROIV has a market cap of 20.7B. Regarding current trading prices, PPBT is priced at $4.49, while ROIV trades at $28.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ROIV's P/E ratio is -24.74. In terms of profitability, PPBT's ROE is -0.10%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, PPBT is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ROIV's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PPBT is priced at $4.49, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PPBT's ROE is -0.10%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, PPBT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check BGNE's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, INCY has a market cap of 20.2B. Regarding current trading prices, PPBT is priced at $4.49, while INCY trades at $98.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas INCY's P/E ratio is 15.80. In terms of profitability, PPBT's ROE is -0.10%, compared to INCY's ROE of +0.29%. Regarding short-term risk, PPBT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check INCY's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, RPRX has a market cap of 19.8B. Regarding current trading prices, PPBT is priced at $4.49, while RPRX trades at $46.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas RPRX's P/E ratio is 25.96. In terms of profitability, PPBT's ROE is -0.10%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, PPBT is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check RPRX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, RVMD has a market cap of 19.7B. Regarding current trading prices, PPBT is priced at $4.49, while RVMD trades at $101.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas RVMD's P/E ratio is -19.66. In terms of profitability, PPBT's ROE is -0.10%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, PPBT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check RVMD's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PPBT is priced at $4.49, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PPBT's ROE is -0.10%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, PPBT is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check DNA-WT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, GMAB has a market cap of 18.1B. Regarding current trading prices, PPBT is priced at $4.49, while GMAB trades at $29.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas GMAB's P/E ratio is 19.12. In terms of profitability, PPBT's ROE is -0.10%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, PPBT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check GMAB's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ASND has a market cap of 14.3B. Regarding current trading prices, PPBT is priced at $4.49, while ASND trades at $233.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ASND's P/E ratio is -52.71. In terms of profitability, PPBT's ROE is -0.10%, compared to ASND's ROE of +1.28%. Regarding short-term risk, PPBT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ASND's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, IONS has a market cap of 13.1B. Regarding current trading prices, PPBT is priced at $4.49, while IONS trades at $81.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas IONS's P/E ratio is -50.40. In terms of profitability, PPBT's ROE is -0.10%, compared to IONS's ROE of -0.69%. Regarding short-term risk, PPBT is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check IONS's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, PPBT is priced at $4.49, while BBIO trades at $63.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas BBIO's P/E ratio is -17.59. In terms of profitability, PPBT's ROE is -0.10%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, PPBT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check BBIO's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PPBT is priced at $4.49, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PPBT's ROE is -0.10%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PPBT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check KRTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, SMMT has a market cap of 12.4B. Regarding current trading prices, PPBT is priced at $4.49, while SMMT trades at $16.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas SMMT's P/E ratio is -13.27. In terms of profitability, PPBT's ROE is -0.10%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, PPBT is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check SMMT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, BMRN has a market cap of 11.9B. Regarding current trading prices, PPBT is priced at $4.49, while BMRN trades at $60.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas BMRN's P/E ratio is 22.94. In terms of profitability, PPBT's ROE is -0.10%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, PPBT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check BMRN's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, PPBT is priced at $4.49, while EXEL trades at $41.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas EXEL's P/E ratio is 15.85. In terms of profitability, PPBT's ROE is -0.10%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, PPBT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check EXEL's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, JAZZ has a market cap of 11.5B. Regarding current trading prices, PPBT is priced at $4.49, while JAZZ trades at $190.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas JAZZ's P/E ratio is -32.10. In terms of profitability, PPBT's ROE is -0.10%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, PPBT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check JAZZ's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, MDGL has a market cap of 9.8B. Regarding current trading prices, PPBT is priced at $4.49, while MDGL trades at $427.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas MDGL's P/E ratio is -33.64. In terms of profitability, PPBT's ROE is -0.10%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, PPBT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check MDGL's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, IBRX has a market cap of 9.6B. Regarding current trading prices, PPBT is priced at $4.49, while IBRX trades at $10.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas IBRX's P/E ratio is -23.85. In terms of profitability, PPBT's ROE is -0.10%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, PPBT is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check IBRX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PPBT is priced at $4.49, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PPBT's ROE is -0.10%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PPBT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check RXDX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, PPBT is priced at $4.49, while TECH trades at $57.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas TECH's P/E ratio is 111.32. In terms of profitability, PPBT's ROE is -0.10%, compared to TECH's ROE of +0.04%. Regarding short-term risk, PPBT is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check TECH's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, PPBT is priced at $4.49, while PCVX trades at $61.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas PCVX's P/E ratio is -12.73. In terms of profitability, PPBT's ROE is -0.10%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, PPBT is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check PCVX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ARWR has a market cap of 8.9B. Regarding current trading prices, PPBT is priced at $4.49, while ARWR trades at $63.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ARWR's P/E ratio is 39.56. In terms of profitability, PPBT's ROE is -0.10%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, PPBT is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ARWR's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PPBT is priced at $4.49, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PPBT's ROE is -0.10%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PPBT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check IMGN's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PPBT is priced at $4.49, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PPBT's ROE is -0.10%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, PPBT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check BPMC's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, AXSM has a market cap of 8.3B. Regarding current trading prices, PPBT is priced at $4.49, while AXSM trades at $164.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas AXSM's P/E ratio is -35.11. In terms of profitability, PPBT's ROE is -0.10%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, PPBT is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check AXSM's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, PPBT is priced at $4.49, while HALO trades at $69.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas HALO's P/E ratio is 27.16. In terms of profitability, PPBT's ROE is -0.10%, compared to HALO's ROE of +0.93%. Regarding short-term risk, PPBT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check HALO's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PPBT is priced at $4.49, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CERE's P/E ratio is -16.47. In terms of profitability, PPBT's ROE is -0.10%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PPBT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CERE's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, KRYS has a market cap of 8.1B. Regarding current trading prices, PPBT is priced at $4.49, while KRYS trades at $267.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas KRYS's P/E ratio is 40.36. In terms of profitability, PPBT's ROE is -0.10%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PPBT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check KRYS's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, PPBT is priced at $4.49, while ABVX trades at $115.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ABVX's P/E ratio is -23.19. In terms of profitability, PPBT's ROE is -0.10%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, PPBT is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ABVX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CYTK has a market cap of 7.6B. Regarding current trading prices, PPBT is priced at $4.49, while CYTK trades at $60.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CYTK's P/E ratio is -9.88. In terms of profitability, PPBT's ROE is -0.10%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, PPBT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CYTK's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PPBT is priced at $4.49, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PPBT's ROE is -0.10%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, PPBT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check MTSR's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, NUVL has a market cap of 7.4B. Regarding current trading prices, PPBT is priced at $4.49, while NUVL trades at $100.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas NUVL's P/E ratio is -19.13. In terms of profitability, PPBT's ROE is -0.10%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, PPBT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check NUVL's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, KYMR has a market cap of 7.3B. Regarding current trading prices, PPBT is priced at $4.49, while KYMR trades at $89.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas KYMR's P/E ratio is -25.37. In terms of profitability, PPBT's ROE is -0.10%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, PPBT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check KYMR's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, PPBT is priced at $4.49, while PRAX trades at $336.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas PRAX's P/E ratio is -25.98. In terms of profitability, PPBT's ROE is -0.10%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, PPBT is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check PRAX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PPBT is priced at $4.49, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PPBT's ROE is -0.10%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, PPBT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check MRUS's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, PPBT is priced at $4.49, while BLTE trades at $181.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas BLTE's P/E ratio is -98.91. In terms of profitability, PPBT's ROE is -0.10%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, PPBT is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check BLTE's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ACLX has a market cap of 6.6B. Regarding current trading prices, PPBT is priced at $4.49, while ACLX trades at $113.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ACLX's P/E ratio is -28.96. In terms of profitability, PPBT's ROE is -0.10%, compared to ACLX's ROE of -0.73%. Regarding short-term risk, PPBT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ACLX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PPBT is priced at $4.49, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas RETA's P/E ratio is -66.29. In terms of profitability, PPBT's ROE is -0.10%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PPBT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check RETA's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, COGT has a market cap of 6.3B. Regarding current trading prices, PPBT is priced at $4.49, while COGT trades at $38.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas COGT's P/E ratio is -17.99. In terms of profitability, PPBT's ROE is -0.10%, compared to COGT's ROE of -1.00%. Regarding short-term risk, PPBT is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check COGT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, PPBT is priced at $4.49, while RYTM trades at $93.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas RYTM's P/E ratio is -29.91. In terms of profitability, PPBT's ROE is -0.10%, compared to RYTM's ROE of -1.84%. Regarding short-term risk, PPBT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check RYTM's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CRSP has a market cap of 5.8B. Regarding current trading prices, PPBT is priced at $4.49, while CRSP trades at $59.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CRSP's P/E ratio is -9.30. In terms of profitability, PPBT's ROE is -0.10%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, PPBT is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CRSP's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, PTGX has a market cap of 5.8B. Regarding current trading prices, PPBT is priced at $4.49, while PTGX trades at $92.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas PTGX's P/E ratio is 139.52. In terms of profitability, PPBT's ROE is -0.10%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, PPBT is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check PTGX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CAI has a market cap of 5.7B. Regarding current trading prices, PPBT is priced at $4.49, while CAI trades at $20.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CAI's P/E ratio is -5.72. In terms of profitability, PPBT's ROE is -0.10%, compared to CAI's ROE of +1.97%. Regarding short-term risk, PPBT is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CAI's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, IMVT has a market cap of 5.6B. Regarding current trading prices, PPBT is priced at $4.49, while IMVT trades at $27.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas IMVT's P/E ratio is -10.39. In terms of profitability, PPBT's ROE is -0.10%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, PPBT is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check IMVT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PPBT is priced at $4.49, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PPBT's ROE is -0.10%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, PPBT is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CDTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PPBT is priced at $4.49, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PPBT's ROE is -0.10%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PPBT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ABCM's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PPBT is priced at $4.49, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PPBT's ROE is -0.10%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PPBT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ISEE's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, PPBT is priced at $4.49, while PTCT trades at $65.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas PTCT's P/E ratio is 7.93. In terms of profitability, PPBT's ROE is -0.10%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, PPBT is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check PTCT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, PPBT is priced at $4.49, while FBIOX trades at $26.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas FBIOX's P/E ratio is N/A. In terms of profitability, PPBT's ROE is -0.10%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, PPBT is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check FBIOX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CELC has a market cap of 5.2B. Regarding current trading prices, PPBT is priced at $4.49, while CELC trades at $110.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CELC's P/E ratio is -30.36. In terms of profitability, PPBT's ROE is -0.10%, compared to CELC's ROE of -1.79%. Regarding short-term risk, PPBT is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CELC's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, PPBT is priced at $4.49, while ALKS trades at $30.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ALKS's P/E ratio is 14.97. In terms of profitability, PPBT's ROE is -0.10%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, PPBT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ALKS's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, TGTX has a market cap of 4.8B. Regarding current trading prices, PPBT is priced at $4.49, while TGTX trades at $29.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas TGTX's P/E ratio is 10.86. In terms of profitability, PPBT's ROE is -0.10%, compared to TGTX's ROE of +1.33%. Regarding short-term risk, PPBT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check TGTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, PPBT is priced at $4.49, while MIRM trades at $90.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas MIRM's P/E ratio is -109.87. In terms of profitability, PPBT's ROE is -0.10%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, PPBT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check MIRM's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CGON has a market cap of 4.7B. Regarding current trading prices, PPBT is priced at $4.49, while CGON trades at $57.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CGON's P/E ratio is -28.68. In terms of profitability, PPBT's ROE is -0.10%, compared to CGON's ROE of -0.23%. Regarding short-term risk, PPBT is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CGON's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, SRRK has a market cap of 4.5B. Regarding current trading prices, PPBT is priced at $4.49, while SRRK trades at $43.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas SRRK's P/E ratio is -14.05. In terms of profitability, PPBT's ROE is -0.10%, compared to SRRK's ROE of -1.22%. Regarding short-term risk, PPBT is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check SRRK's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PPBT is priced at $4.49, while FOLD trades at $14.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas FOLD's P/E ratio is -359.25. In terms of profitability, PPBT's ROE is -0.10%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PPBT is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check FOLD's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PPBT is priced at $4.49, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PPBT's ROE is -0.10%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, PPBT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check AKRO's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PPBT is priced at $4.49, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PPBT's ROE is -0.10%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PPBT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ALPN's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PPBT is priced at $4.49, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas OPT's P/E ratio is -1.52. In terms of profitability, PPBT's ROE is -0.10%, compared to OPT's ROE of +0.88%. Regarding short-term risk, PPBT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check OPT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, PPBT is priced at $4.49, while ERAS trades at $13.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ERAS's P/E ratio is -31.77. In terms of profitability, PPBT's ROE is -0.10%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, PPBT is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ERAS's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CRNX has a market cap of 4.2B. Regarding current trading prices, PPBT is priced at $4.49, while CRNX trades at $40.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CRNX's P/E ratio is -9.06. In terms of profitability, PPBT's ROE is -0.10%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, PPBT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CRNX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ACAD has a market cap of 4.2B. Regarding current trading prices, PPBT is priced at $4.49, while ACAD trades at $23.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ACAD's P/E ratio is 15.83. In terms of profitability, PPBT's ROE is -0.10%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, PPBT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ACAD's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PPBT is priced at $4.49, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PPBT's ROE is -0.10%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PPBT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check MRTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, PPBT is priced at $4.49, while NAMS trades at $33.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas NAMS's P/E ratio is -20.62. In terms of profitability, PPBT's ROE is -0.10%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, PPBT is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check NAMS's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, PPBT is priced at $4.49, while VKTX trades at $33.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas VKTX's P/E ratio is -10.61. In terms of profitability, PPBT's ROE is -0.10%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, PPBT is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check VKTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, LGND has a market cap of 3.9B. Regarding current trading prices, PPBT is priced at $4.49, while LGND trades at $199.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas LGND's P/E ratio is 87.36. In terms of profitability, PPBT's ROE is -0.10%, compared to LGND's ROE of +0.14%. Regarding short-term risk, PPBT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check LGND's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, APGE has a market cap of 3.8B. Regarding current trading prices, PPBT is priced at $4.49, while APGE trades at $69.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas APGE's P/E ratio is -15.99. In terms of profitability, PPBT's ROE is -0.10%, compared to APGE's ROE of -0.39%. Regarding short-term risk, PPBT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check APGE's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, TERN has a market cap of 3.8B. Regarding current trading prices, PPBT is priced at $4.49, while TERN trades at $42.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas TERN's P/E ratio is -41.29. In terms of profitability, PPBT's ROE is -0.10%, compared to TERN's ROE of -0.30%. Regarding short-term risk, PPBT is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check TERN's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CORT has a market cap of 3.8B. Regarding current trading prices, PPBT is priced at $4.49, while CORT trades at $35.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CORT's P/E ratio is 43.54. In terms of profitability, PPBT's ROE is -0.10%, compared to CORT's ROE of +0.15%. Regarding short-term risk, PPBT is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CORT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PPBT is priced at $4.49, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PPBT's ROE is -0.10%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PPBT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check RYZB's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PPBT is priced at $4.49, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PPBT's ROE is -0.10%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PPBT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CBAY's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ADMA has a market cap of 3.7B. Regarding current trading prices, PPBT is priced at $4.49, while ADMA trades at $16.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ADMA's P/E ratio is 18.10. In terms of profitability, PPBT's ROE is -0.10%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, PPBT is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ADMA's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, GPCR has a market cap of 3.6B. Regarding current trading prices, PPBT is priced at $4.49, while GPCR trades at $63.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas GPCR's P/E ratio is -17.21. In terms of profitability, PPBT's ROE is -0.10%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, PPBT is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check GPCR's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CNTA has a market cap of 3.6B. Regarding current trading prices, PPBT is priced at $4.49, while CNTA trades at $26.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CNTA's P/E ratio is -14.21. In terms of profitability, PPBT's ROE is -0.10%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, PPBT is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CNTA's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PPBT is priced at $4.49, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PPBT's ROE is -0.10%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, PPBT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check SWTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, XENE has a market cap of 3.3B. Regarding current trading prices, PPBT is priced at $4.49, while XENE trades at $43.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas XENE's P/E ratio is -11.11. In terms of profitability, PPBT's ROE is -0.10%, compared to XENE's ROE of -0.55%. Regarding short-term risk, PPBT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check XENE's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, PPBT is priced at $4.49, while DNLI trades at $21.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas DNLI's P/E ratio is -7.25. In terms of profitability, PPBT's ROE is -0.10%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, PPBT is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check DNLI's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ARQT has a market cap of 3.3B. Regarding current trading prices, PPBT is priced at $4.49, while ARQT trades at $25.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ARQT's P/E ratio is -79.35. In terms of profitability, PPBT's ROE is -0.10%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, PPBT is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ARQT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, KNSA has a market cap of 3.3B. Regarding current trading prices, PPBT is priced at $4.49, while KNSA trades at $44.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas KNSA's P/E ratio is 96.72. In terms of profitability, PPBT's ROE is -0.10%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, PPBT is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check KNSA's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, EWTX has a market cap of 3.2B. Regarding current trading prices, PPBT is priced at $4.49, while EWTX trades at $29.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas EWTX's P/E ratio is -19.39. In terms of profitability, PPBT's ROE is -0.10%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, PPBT is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check EWTX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, TARS has a market cap of 3.2B. Regarding current trading prices, PPBT is priced at $4.49, while TARS trades at $75.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas TARS's P/E ratio is -37.95. In terms of profitability, PPBT's ROE is -0.10%, compared to TARS's ROE of -0.20%. Regarding short-term risk, PPBT is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check TARS's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, PPBT is priced at $4.49, while ALMS trades at $29.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas ALMS's P/E ratio is -13.81. In terms of profitability, PPBT's ROE is -0.10%, compared to ALMS's ROE of -0.76%. Regarding short-term risk, PPBT is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check ALMS's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, VCYT has a market cap of 2.9B. Regarding current trading prices, PPBT is priced at $4.49, while VCYT trades at $36.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas VCYT's P/E ratio is 96.29. In terms of profitability, PPBT's ROE is -0.10%, compared to VCYT's ROE of +0.05%. Regarding short-term risk, PPBT is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check VCYT's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, BEAM has a market cap of 2.9B. Regarding current trading prices, PPBT is priced at $4.49, while BEAM trades at $28.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas BEAM's P/E ratio is -6.45. In terms of profitability, PPBT's ROE is -0.10%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, PPBT is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check BEAM's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, PPBT is priced at $4.49, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas MORF's P/E ratio is -14.88. In terms of profitability, PPBT's ROE is -0.10%, compared to MORF's ROE of -0.29%. Regarding short-term risk, PPBT is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check MORF's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, PPBT is priced at $4.49, while VERA trades at $40.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas VERA's P/E ratio is -10.22. In terms of profitability, PPBT's ROE is -0.10%, compared to VERA's ROE of -0.60%. Regarding short-term risk, PPBT is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check VERA's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, PPBT is priced at $4.49, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas MOR's P/E ratio is -12.64. In terms of profitability, PPBT's ROE is -0.10%, compared to MOR's ROE of -1.84%. Regarding short-term risk, PPBT is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check MOR's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, CPRX has a market cap of 2.8B. Regarding current trading prices, PPBT is priced at $4.49, while CPRX trades at $23.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas CPRX's P/E ratio is 13.50. In terms of profitability, PPBT's ROE is -0.10%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PPBT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check CPRX's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, IDYA has a market cap of 2.8B. Regarding current trading prices, PPBT is priced at $4.49, while IDYA trades at $32.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas IDYA's P/E ratio is -25.16. In terms of profitability, PPBT's ROE is -0.10%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, PPBT is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check IDYA's competition here

PPBT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PPBT stands at 6.1K. In comparison, NAMSW has a market cap of 2.8B. Regarding current trading prices, PPBT is priced at $4.49, while NAMSW trades at $25.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PPBT currently has a P/E ratio of -0.01, whereas NAMSW's P/E ratio is N/A. In terms of profitability, PPBT's ROE is -0.10%, compared to NAMSW's ROE of -0.27%. Regarding short-term risk, PPBT is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for PPBT.Check NAMSW's competition here